Shangmei Stock: Signed a strategic cooperation framework agreement with Kunshan Kaituo, a subsidiary of Kaituo Pharmaceuticals.

The announcement from Shangmei Corporation states that the company has entered into a strategic cooperation framework agreement with Suzhou Kotop Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Kotop Pharmaceuticals, in the field of cosmetics, which includes exclusive clauses. The agreement pertains to the rapid commercialization of the cosmetic ingredient KT-939 with whitening and spot-removing effects. According to the framework agreement, both parties will collaborate on the registration of KT-939 in China as a new ingredient in cosmetics, as well as the registration of cosmetic products with KT-939 as the core ingredient. They also plan to jointly conduct research and customization of effective ingredients to build a domestically-produced whitening product with industry influence based on KT-939.